Piper Sandler analyst Matt O'Brien lowered the firm's price target on Globus Medical to $100 from $115 and keeps an Overweight rating on the shares. The firm is updating a few of its models to better align with quarterly cadence, company guidance and consensus estimates. For Globus Medical, Piper updates 2026 quarterly top-line cadence to better contemplate business seasonality and out-year estimates to align more with consensus.
